HTN

ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD

Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD Protocol #: ALN-AGT01-008 Indication: HTN (Uncontrolled) GFR: <60 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD Read More »

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure

Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Protocol #: D6972C00002 Indication: CKD & HTN GFR: 30-75 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Read More »